FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016016176> ?p ?o ?g. }

• W2016016176 endingPage "41" @default.
• W2016016176 startingPage "35" @default.
• W2016016176 abstract "The aim of this study was to explore the clinical value of gemcitabine combined with capecitabine (GC) in heavily pre-treated patients with metastatic breast cancer.All patients had failed anthracyclines and taxanes. In 14 patients (41%), more than two metastatic sites were diagnosed with bone (68%) and liver (62%) being the most prominent. Gemcitabine (1,250 mg/m(2), d1+8) and capecitabine (800 mg/m(2) twice daily, d1-14) were administered according to a 3-week schedule. The majority of patients received GC as 3rd or 4th line chemotherapy for metastatic disease. Laboratory tests were done on day 1+8 in cycles. Subjective toxicity was recorded according to the NCI-CTC v. 2.0 criteria. Tumour evaluations were done every 12th week according to the RECIST criteria. The primary objective was to investigate time to progression. Secondary objectives were response rate with special focus on the proportion of patients achieving PR or SD of at least three months, toxicity and survival.A total of 34 patients were enrolled. All subjects are eligible for toxicity, response and time to event analyses. Treatment was given until progressive disease, severe toxicity or until the patient wanted to withdraw. The Kaplan-Meier median time to progression was estimated to 4.3 months and the overall survival time to 13.7 months. Partial response was noted in 12 of 29 evaluable patients (41%). The best outcome amongst remaining patients was stable disease in nine (31%) or tumour progression in eight (28%). A delay of disease progression of more than three months was noted in 53% of the study population. The main side effect was granulocytopenia with 44% and 15% of patients suffering from grade 3 or grade 4 events respectively however, no neutropenic infections were observed. Pre-dominant grade 3 subjective toxicities were: fatigue (21% of patients) and hand-foot syndrome (15% of patients).We investigated the value of the GC combination as a treatment for late stage breast cancer patients. Tumour progression was delayed and the treatment was well tolerated. We believe that the GC therapy can achieve meaningful palliation." @default.
• W2016016176 created "2016-06-24" @default.
• W2016016176 creator A5006055583 @default.
• W2016016176 creator A5022166017 @default.
• W2016016176 creator A5022391459 @default.
• W2016016176 creator A5048816555 @default.
• W2016016176 creator A5051110265 @default.
• W2016016176 creator A5053115455 @default.
• W2016016176 creator A5065355046 @default.
• W2016016176 creator A5087362691 @default.
• W2016016176 creator A5087662577 @default.
• W2016016176 date "2009-10-20" @default.
• W2016016176 modified "2023-09-27" @default.
• W2016016176 title "Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study" @default.
• W2016016176 cites W1984254136 @default.
• W2016016176 cites W2021371461 @default.
• W2016016176 cites W2051804590 @default.
• W2016016176 cites W2084095038 @default.
• W2016016176 cites W2086140322 @default.
• W2016016176 cites W2115428190 @default.
• W2016016176 cites W2131770017 @default.
• W2016016176 cites W2139977268 @default.
• W2016016176 cites W2159329940 @default.
• W2016016176 cites W2242556880 @default.
• W2016016176 cites W2589931982 @default.
• W2016016176 cites W5038423 @default.
• W2016016176 doi "https://doi.org/10.3109/02841860903268031" @default.
• W2016016176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19839920" @default.
• W2016016176 hasPublicationYear "2009" @default.
• W2016016176 type Work @default.
• W2016016176 sameAs 2016016176 @default.
• W2016016176 citedByCount "10" @default.
• W2016016176 countsByYear W20160161762012 @default.
• W2016016176 countsByYear W20160161762013 @default.
• W2016016176 countsByYear W20160161762014 @default.
• W2016016176 countsByYear W20160161762015 @default.
• W2016016176 countsByYear W20160161762016 @default.
• W2016016176 countsByYear W20160161762023 @default.
• W2016016176 crossrefType "journal-article" @default.
• W2016016176 hasAuthorship W2016016176A5006055583 @default.
• W2016016176 hasAuthorship W2016016176A5022166017 @default.
• W2016016176 hasAuthorship W2016016176A5022391459 @default.
• W2016016176 hasAuthorship W2016016176A5048816555 @default.
• W2016016176 hasAuthorship W2016016176A5051110265 @default.
• W2016016176 hasAuthorship W2016016176A5053115455 @default.
• W2016016176 hasAuthorship W2016016176A5065355046 @default.
• W2016016176 hasAuthorship W2016016176A5087362691 @default.
• W2016016176 hasAuthorship W2016016176A5087662577 @default.
• W2016016176 hasBestOaLocation W20160161761 @default.
• W2016016176 hasConcept C121608353 @default.
• W2016016176 hasConcept C126322002 @default.
• W2016016176 hasConcept C141071460 @default.
• W2016016176 hasConcept C143998085 @default.
• W2016016176 hasConcept C2775930923 @default.
• W2016016176 hasConcept C2776694085 @default.
• W2016016176 hasConcept C2776802502 @default.
• W2016016176 hasConcept C2777511904 @default.
• W2016016176 hasConcept C2777909004 @default.
• W2016016176 hasConcept C2778822529 @default.
• W2016016176 hasConcept C2779984678 @default.
• W2016016176 hasConcept C2780258809 @default.
• W2016016176 hasConcept C29730261 @default.
• W2016016176 hasConcept C526805850 @default.
• W2016016176 hasConcept C530470458 @default.
• W2016016176 hasConcept C71924100 @default.
• W2016016176 hasConceptScore W2016016176C121608353 @default.
• W2016016176 hasConceptScore W2016016176C126322002 @default.
• W2016016176 hasConceptScore W2016016176C141071460 @default.
• W2016016176 hasConceptScore W2016016176C143998085 @default.
• W2016016176 hasConceptScore W2016016176C2775930923 @default.
• W2016016176 hasConceptScore W2016016176C2776694085 @default.
• W2016016176 hasConceptScore W2016016176C2776802502 @default.
• W2016016176 hasConceptScore W2016016176C2777511904 @default.
• W2016016176 hasConceptScore W2016016176C2777909004 @default.
• W2016016176 hasConceptScore W2016016176C2778822529 @default.
• W2016016176 hasConceptScore W2016016176C2779984678 @default.
• W2016016176 hasConceptScore W2016016176C2780258809 @default.
• W2016016176 hasConceptScore W2016016176C29730261 @default.
• W2016016176 hasConceptScore W2016016176C526805850 @default.
• W2016016176 hasConceptScore W2016016176C530470458 @default.
• W2016016176 hasConceptScore W2016016176C71924100 @default.
• W2016016176 hasIssue "1" @default.
• W2016016176 hasLocation W20160161761 @default.
• W2016016176 hasLocation W20160161762 @default.
• W2016016176 hasOpenAccess W2016016176 @default.
• W2016016176 hasPrimaryLocation W20160161761 @default.
• W2016016176 hasRelatedWork W181195935 @default.
• W2016016176 hasRelatedWork W1982182115 @default.
• W2016016176 hasRelatedWork W2016016176 @default.
• W2016016176 hasRelatedWork W2024302667 @default.
• W2016016176 hasRelatedWork W2085123446 @default.
• W2016016176 hasRelatedWork W2139955290 @default.
• W2016016176 hasRelatedWork W2388022328 @default.
• W2016016176 hasRelatedWork W2436215013 @default.
• W2016016176 hasRelatedWork W2590140540 @default.
• W2016016176 hasRelatedWork W4248935919 @default.
• W2016016176 hasVolume "49" @default.
• W2016016176 isParatext "false" @default.

• next